The Telix Pharmaceuticals Ltd (ASX: TLX) share price is heading north during late morning trade following a company announcement.
At the time of writing, the biotechnology company’s shares are selling for $4.56 apiece, up 9.88%.
What did Telix announce?
Investors are pushing Telix shares higher after investors digest the company’s latest announcement to the ASX.
According to its release, Telix advised it has been granted Orphan Drug Designation (ODD) from the United States Food and Drug Administration (FDA) for its bone marrow conditioning treatment, TLX66.
Bone marrow conditioning is performed prior to hematopoietic stem cell transplantation (HSCT).
The latter is a procedure where a patient’s healthy stem cells are collected from blood or bone marrow before treatment. The stem cells are then safely stored, and given back to the patient after treatment.
The Orphan Drug Act was created by the FDA to motivate biopharmaceutical companies in developing potential medicines for rare or ‘orphan’ diseases. The ODD provides preferential treatment that enhances a company’s standing with the agency.
HSCT is being used increasingly in malignant hematological conditions, such as multiple myeloma and acute myeloid leukemia, and in non-hematological malignancies and rare/immune-mediated diseases.
In 2018, more than 22,700 HSCTs were performed in the United States.
The welcomed decision enables the company to receive special benefits of achieving incentivised targets. This includes eligibility for seven years of market exclusivity after FDA approval, discounted tax credits of 50% of drug testing costs, additional protocol assistance, reduced review times and specific marketing authorisation application fees waived.
Telix chief medical officer, Dr Colin Hayward added:
The granting of an Orphan Drug Designation by the FDA for TLX66, combined with recent encouraging data from prior studies in hematological malignancies and autoimmune disease provides a strong impetus to advance our development plans for TLX66.
This treatment has potential application in a number of hematological cancers and rare diseases and potentially also in the future for conditioning for cell and gene therapies.
Telix share price summary
It’s been a challenging couple of months for Telix shareholders, with the company’s share price down 42% in 2022.
However, when looking at the past 12 months, the company’s shares are hovering around 2% higher.
On valuation grounds, Telix presides a market capitalisation of roughly $1.4 billion.
The post Here’s why the Telix (ASX:TLX) share price is leaping higher today appeared first on The Motley Fool Australia.
Should you invest $1,000 in Telix right now?
Before you consider Telix, you’ll want to hear this.
Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Telix wasn’t one of them.
The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.
*Returns as of January 13th 2022
More reading
- These were the worst performing ASX 200 shares last week
- Why Atlas Arteria, Core Lithium, Premier, and Telix shares are dropping
- Why is the Telix Pharmaceuticals (ASX:TLX) share price plunging 14%?
- 5 profitable small-cap ASX shares to buy right now: Wilsons
Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.
from The Motley Fool Australia https://ift.tt/CUkFTRb
Leave a Reply